Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines

Selma Masri1, Sheryl Phung, Xin Wang

  • 1Division of Tumor Cell Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.

Insights

Aromatase inhibitor resistance in breast cancer involves distinct molecular pathways. Estrogen receptor alpha activation and crosstalk with growth factor signaling contribute to acquired resistance, suggesting new therapeutic strategies.

Area of Science:

  • Molecular Oncology
  • Endocrinology
  • Genomics

Background:

  • Aromatase inhibitors (AIs) are crucial in treating hormone-sensitive breast cancer.
  • Understanding mechanisms of AI resistance is vital for improving patient outcomes.
  • Previous studies suggest diverse resistance pathways beyond estrogen receptor (ER) signaling.

Purpose of the Study:

  • To identify genes and pathways involved in acquired resistance to aromatase inhibitors (AIs).
  • To compare gene expression profiles across different AI-resistant cell lines.
  • To elucidate the role of estrogen receptor alpha (ERalpha) activation in AI resistance.

Main Methods:

  • Microarray analysis of MCF-7aro cells with acquired resistance to letrozole, anastrozole, and exemestane.
  • Comparison with tamoxifen-resistant (T+TAM R) and long-term estrogen-deprived (LTEDaro) cell lines.
  • Hierarchical clustering and genome-wide gene expression profiling.

Main Results:

  • Estrogen-responsive genes were differentially expressed in AI-resistant lines.
  • Non-steroidal AI-resistant lines (letrozole, anastrozole) showed similar profiles, distinct from exemestane-resistant lines.
  • Constitutively active ERalpha was identified in letrozole-, anastrozole-, and LTEDaro-resistant cells, mediating ligand-independent activation.
  • Exemestane resistance involved ER-dependent crosstalk with EGFR signaling.
  • Intermittent exemestane use delayed acquired resistance in preclinical models.

Conclusions:

  • Acquired AI resistance progresses from hormone-dependence to hormone-independence.
  • Distinct mechanisms, including ligand-independent ERalpha activation and ER-EGFR crosstalk, drive resistance.
  • Hormone-independence can occur independently of conventional ER signaling, as seen in LTEDaro cells.